OB/GYN Clinical Alert – August 1, 2012
August 1, 2012
View Issues
-
Long-Acting Reversible Contraception
The authors performed a prospective cohort study, the contraceptive CHOICE Project, in which women in the St. Louis, Missouri, region received a reversible contraceptive method of their choice for up to 3 years at no cost. -
PARP Inhibitor Maintenance SCORES in Ovarian Cancer
Poly(adenosine diphosphate [adp]-ribose) polymerase (PARP) is an enzyme participating in low-fidelity DNA repair of single strand breaks. Pharmacologic inhibition of PARP has shown to be effective in tumors lacking homologous recombination, such as those harboring silencing mutations of BRCA1 and 2. -
10 Years after the WHI: Should This Study Guide Our Thinking About Menopausal Hormone Therapy?
To provide guidance to clinicians on the use of hormone replacement therapy, the authors conducted a systematic review of the randomized, placebo-controlled trials of menopausal hormone therapy published in English since 2002 that assessed primary prevention of chronic conditions. -
Antenatal Steroids and Fetal Lung Maturity
Apropos of the recent emphasis on discouraging elective deliveries prior to 39 weeks, a group from Cincinnati embarked on a study to determine whether steroids had any neonatal benefit in patients delivering between 34 and 39 weeks who had immature amniotic fluid lung profiles. -
Patient Attitudes Toward Treatments for Overactive Bladder
Researchers from duke university and the university of California, San Francisco enrolled 40 patients with symptoms of overactive bladder (OAB), i.e., urgency, frequency, and/or urge incontinence, and 40 patients with no history of OAB symptoms. The women's view of symptoms and treatments were measured with a utility score. -
Pharmacology Watch: FDA Approves First New Anti-Obesity Drug in Years
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions. -
Clinical Briefs in Primary Care supplement